TAKEDA PHARMACEUTICAL COMPANY LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,049 JPY | -0.98% |
|
-2.36% | -0.15% |
| Apr. 18 | Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease | DJ |
| Apr. 16 | Takeda Pharmaceutical to Issue 2nd Hybrid Bonds in Mid-2024 to Refinance 500 Billion Yen 1st Hybrid Bonds | MT |
Presenter SpeechAyako Iwamuro (Executives)[Interpreted] Good evening, everybody, or good morni...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q4 2023 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,089
JPY
Average target price
4,790
JPY
Spread / Average Target
+17.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.15% | 41.16B | |
| +27.97% | 676B | |
| +23.58% | 554B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- Transcript : Takeda Pharmaceutical Company Limited, Q1 2023 Earnings Call, Jul 28, 2022
